Navigation Links
Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
Date:6/2/2009

NIH funds human clinical testing of the cell trafficking MRI reagent, Cell Sense.

Pittsburgh, PA (Vocus) June 2, 2009 -- Celsense, Inc. announced today that it is one of the recipients in a 4-year $1.95M grant from the National Institutes of Health. The funded studies will be the first effort to evaluate Cell Sense, the Company’s fluorocarbon-based magnetic resonance imaging (MRI) cell tracking reagent, for clinical use. Additionally, the studies will garner preliminary data critically important for improving immunotherapeutic delivery strategies in metastatic colorectal (CRC) and other forms of cancer.

The Cell Sense technology makes transplanted cells visible by MRI. Therapeutic cells are labeled ex vivo with the Cell Sense reagent prior to administration to the patient. Cell migration and biodistribution are subsequently monitored using fluorine-19 (19F) MRI or magnetic resonance spectroscopy (MRS). The key advantage of Cell Sense is that the 19F images are extremely selective for the labeled cells, with no background signal from the host’s tissues. Furthermore, accurate cell quantification in regions of interest is possible.

Existing data from pre-clinical studies using human cells show that the Cell Sense reagent is highly biocompatible inside cells and does not affect their innate function. A clinical-grade version of the Cell Sense reagent has been formulated by Celsense, Inc. and is currently being subjected to mandatory in vitro and animal safety studies in preparation for human trials.

To conduct this project, Celsense has partnered with academia, including scientists at Carnegie Mellon University, where the imaging technology was invented in the laboratory of Dr. Ahrens. Also participating is the University of Pittsburgh Cancer Institute (UPCI) which is actively conducting clinical trials using immunotherapeutic dendritic cell (DC) vaccines to treat CRC, directed by Drs. Kalinski and Bartlett.

About Colorectal Cancer (CRC)
CRC is the third leading cancer in the United States and the most common form of gastrointestinal malignancy. CRC accounts for approximately 150,000 new cases annually. Immunotherapeutic interventions using live-cell DC vaccines may potentially be effective in CRC patients. To date, the inability to accurately follow the location of the cells after transfer to the patient is one of the critical bottlenecks in the development and delivery of cancer immunotherapies.

About Cell Sense
Cell Sense (patent-pending) is a fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Labeled cells are transplanted into the patient enabling researchers and clinicians to non-invasively track the administration and migration of therapeutic and/or diagnostic cells using 19F MRI or MRS. Applications include tracking cells in immunotherapy or regenerative medicine as well as diagnosis of inflammatory sites by tracking selected populations of immune cells. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. It is expected that in vivo cellular imaging will routinely be used to provide a surrogate biomarker for certain cellular therapeutic and drug trials.

About Celsense, Inc.
Celsense, Inc. is a biotechnology company offering novel pre-clinical and clinical-grade cellular and molecular imaging agents used to non-invasively monitor biological processes in living systems. The core innovations of the Company involve proprietary imaging agents that can be used to observe the trafficking of cells using magnetic resonance techniques. Celsense’s mission is to be the standard for cellular imaging in human health. For more information, see Celsense.com.

Information Contact: Charlie O’Hanlon, President and CEO of Celsense, Inc.

###

Read the full story at http://www.prweb.com/releases/Celsense/2009-6-1/prweb2483234.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
2. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
3. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
4. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
5. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
6. Genaera Receives Non-Compliance Notice from Nasdaq
7. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
8. Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice
9. NeurogesX Receives European Commission Approval for Qutenza(TM)
10. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
11. GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
Breaking Biology Technology:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
Breaking Biology News(10 mins):